REZOLUTE INC (RZLT)
US76200L3096 - Common Stock
Overall RZLT gets a fundamental rating of 3 out of 10. We evaluated RZLT against 572 industry peers in the Biotechnology industry. RZLT has a great financial health rating, but its profitability evaluates not so good. RZLT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year RZLT has reported negative net income.
In the past year RZLT has reported a negative cash flow from operations.
In the past 5 years RZLT always reported negative net income.
RZLT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RZLT has a Return On Assets (-56.16%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -61.10%, RZLT is doing good in the industry, outperforming 60.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.16% | ||
| ROE | -61.1% | ||
| ROIC | N/A |
ROA(3y)-39.29%
ROA(5y)-113.74%
ROE(3y)-50.7%
ROE(5y)-448.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RZLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, RZLT has more shares outstanding
The number of shares outstanding for RZLT has been increased compared to 5 years ago.
RZLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 11.62 indicates that RZLT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.62, RZLT belongs to the top of the industry, outperforming 88.14% of the companies in the same industry.
RZLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 11.62 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 13.79 indicates that RZLT has no problem at all paying its short term obligations.
RZLT has a Current ratio of 13.79. This is amongst the best in the industry. RZLT outperforms 87.96% of its industry peers.
RZLT has a Quick Ratio of 13.79. This indicates that RZLT is financially healthy and has no problem in meeting its short term obligations.
RZLT has a better Quick ratio (13.79) than 87.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.79 | ||
| Quick Ratio | 13.79 |
3. Growth
3.1 Past
The earnings per share for RZLT have decreased strongly by -16.51% in the last year.
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
RZLT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.39% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.95%
EPS Next 2Y-2.15%
EPS Next 3Y-5.7%
EPS Next 5Y22.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RZLT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RZLT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RZLT's earnings are expected to decrease with -5.70% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.15%
EPS Next 3Y-5.7%
5. Dividend
5.1 Amount
RZLT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REZOLUTE INC
NASDAQ:RZLT (1/14/2025, 8:04:03 PM)
After market: 4.72 0 (0%)4.72
-0.03 (-0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.68%
Inst Owner Change0%
Ins Owners0.78%
Ins Owner Change0.02%
Market Cap273.48M
Analysts86.25
Price Target13.26 (180.93%)
Short Float %2.47%
Short Ratio3.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.07%
Min EPS beat(2)-32.5%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)1.33%
Min EPS beat(4)-32.5%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)7.64%
EPS beat(12)9
Avg EPS beat(12)11.51%
EPS beat(16)11
Avg EPS beat(16)10.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.44%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.41 | ||
| P/tB | 2.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.27
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS1.96
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.16% | ||
| ROE | -61.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-39.29%
ROA(5y)-113.74%
ROE(3y)-50.7%
ROE(5y)-448.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.79 | ||
| Quick Ratio | 13.79 | ||
| Altman-Z | 11.62 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
EPS Next Y-21.95%
EPS Next 2Y-2.15%
EPS Next 3Y-5.7%
EPS Next 5Y22.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-170.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-170.31%
OCF growth 3YN/A
OCF growth 5YN/A